NCT04357457View on ClinicalTrials.gov

Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia

PHASE3CompletedINTERVENTIONAL

Enrollment

181

Participants

Timeline

Start Date

September 3, 2020

Primary Completion Date

October 1, 2021

Study Completion Date

December 17, 2021

Conditions

Covid 19Hypoxemic Respiratory Failure

Interventions

DRUG

Almitrine

Intravenous almitrine at a dose of 2 µg.kg-1.min-1 during 5 days

DRUG

Placebo

Intravenous glucose 5% during 5 days

Trial Locations (1)

Unknown

Hospital Pitié-Salpêtrière, Paris

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT04357457 - Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia | Biotech Hunter | Biotech Hunter